Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

ClinicalTrials.gov ID: NCT04993768

Public ClinicalTrials.gov record NCT04993768. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.

Study identification

NCT ID
NCT04993768
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Transposon Therapeutics, Inc.
Industry
Enrollment
42 participants

Conditions and interventions

Eligibility (public fields only)

Age range
41 Years to 86 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 11, 2021
Primary completion
Feb 23, 2024
Completion
Mar 23, 2024
Last update posted
Apr 7, 2026

2021 – 2024

United States locations

U.S. sites
14
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
St. Joseph's Hospital and Medical Center, Barrow Neurological Institute Phoenix Arizona 85013
UC San Diego Altman Clinical And Translational Research Institute La Jolla California 92037
UCSF Neurosciences Clinical Research Unit (NCRU) San Francisco California 94158
Rocky Mountain Movement Disorders Center Englewood Colorado 80113
Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida 33486
UFHealth Fixel Institute for Neurological Diseases Gainesville Florida 32608
Johns Hopkins University School of Medicine Baltimore Maryland 21287
Massachusetts General Hospital Boston Massachusetts 02114
Quest Research Institute Farmington Hills Michigan 48334
Mayo Clinic Rochester Minnesota 55905
Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas Nevada 89106
Irving Center for Clinical and Translational Research New York New York 10032
Hospital of the University of Pennsylvania Philadelphia Pennsylvania 19104
University of Texas Southwestern Medical Center Dallas Texas 75390

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04993768, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04993768 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →